Researchers at the Vall d’Hebron Institute of Oncology have made significant progress in systemic targeted therapy for pseudomyxoma peritonei.
- Treatment with BRAF inhibitors reduces tumor cell proliferation in subcutaneous BRAFV600E PMP-PDX tumors without impacting apoptosis
- Pseudomyxoma peritonei is a rare cancer with limited treatment options such as surgery and chemotherapy
- A preclinical study demonstrates the efficacy of BRAF inhibitor encorafenib in reducing tumor growth and prolonging survival in mice with pseudomyxoma peritonei
- Researchers developed patient-derived mouse models with identified KRAS and BRAF targets to guide molecular targeted therapies
- Intra-abdominal mucin biopsy was used to detect circulating tumor DNA for identifying druggable mutations like BRAFV600E, suggesting systemic targeted therapy as a potential new treatment option.
Source link
Oncology